Bolt Biotherapeutics Inc. announced the appointment of Kathleen LaPorte, to its Board of Directors. The addition increases Bolt's board to eight members. Ms. LaPorte, who will serve as Chair of Bolt's Audit Committee, has more than 30 years of experience in building and operating private and public biotech companies. Ms. LaPorte currently serves as a director for Elysium Therapeutics, Precipio Diagnostics, and D2G Oncology.